Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it granted stock options to purchase an aggregate of 461,000 shares of Tenaya common stock to three new non-executive employees in connection with the commencement of their employment. The stock options have an exerci...
Xos Delivers First Quarter Results, Highlighting GAAP Margin Gains Achieved positive gross margin of approximately 20%, for the first quarter 2025 LOS ANGELES, May 14, 2025 (GLOBE NEWSWIRE) -- Xos, Inc. (NASDAQ: XOS) (“Xos” or the “Company”), a leading electric truck manufacturer and fleet services provider, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Highlights: Delivered 29 units and generated $5.9 million in revenue during the first quarter of 2025, compared to 62 units and $13.2 million in revenue in the first...
Tenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual Meeting Advancements Lay the Groundwork for Future Genetic Medicines for Rare and Prevalent Forms of Heart Disease SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it will present five abstracts at the upcoming American Society ...
Xos, Inc. Announces First Quarter 2025 Earnings Release Date and Conference Call LOS ANGELES, May 09, 2025 (GLOBE NEWSWIRE) -- Xos, Inc. (NASDAQ: XOS), a leading electric truck manufacturer and fleet services provider, announced it is scheduling the release of its first quarter 2025 operating results on Wednesday, May 14, 2025 after the close of the U.S. financial markets. Management will host a conference call to discuss these financial results at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time that same day. Conference Call and Webcast Details Date / Time:Wednesday, May 14, 2025, at 4...
Appian Announces First Quarter 2025 Financial Results Cloud subscriptions revenue increased 15% year-over-year to $99.8 million and generated operating cash flow of $45.0 million MCLEAN, Va., May 08, 2025 (GLOBE NEWSWIRE) -- Appian (Nasdaq: APPN) today announced financial results for the first quarter ended March 31, 2025. “In Q1, Appian continued to demonstrate our earnings potential, with narrowing net losses, our third straight quarter of positive adjusted EBITDA, and $45 million in operating cash flow,” said Matt Calkins, CEO & Founder. First Quarter 2025 Financial Highlights: Re...
Tenaya Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update Interim Data from Low Dose Cohort in MyPEAKTM-1 Clinical Trial of TN-201 Showed Encouraging Safety Profile, Transduction and Expression, Plus Improvements in Hypertrophy and NYHA Classification RIDGE Natural History and Seroprevalence Study Highlights Significant Disease Burden and Unmet Need Among Adults with PKP2-associated ARVC Data Readouts for TN-201 and TN-401 Clinical Programs On Track for the Second Half of 2025 Cash Runway Extended into Second Half of 2026 SOUTH SAN FRANCISCO, Calif., ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.